160 related articles for article (PubMed ID: 31866530)
1. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
[TBL] [Abstract][Full Text] [Related]
2. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
3. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies.
Hidayat K; Du X; Wu MJ; Shi BM
Obes Rev; 2019 Oct; 20(10):1494-1503. PubMed ID: 31250977
[TBL] [Abstract][Full Text] [Related]
4. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
5. The impact of diabetes and diabetes medications on bone health.
Gilbert MP; Pratley RE
Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213
[TBL] [Abstract][Full Text] [Related]
6. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
Kohler S; Kaspers S; Salsali A; Zeller C; Woerle HJ
Diabetes Care; 2018 Aug; 41(8):1809-1816. PubMed ID: 29907581
[TBL] [Abstract][Full Text] [Related]
8. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
Dai X; Wang H; Jing Z; Fu P
Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylureas use and fractures risk in elderly patients with type 2 diabetes mellitus: a meta-analysis study.
Tao Y; E M; Shi J; Zhang Z
Aging Clin Exp Res; 2021 Aug; 33(8):2133-2139. PubMed ID: 33104983
[TBL] [Abstract][Full Text] [Related]
10. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
Wu Y; Liu HB; Shi XF; Song Y
PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Pladevall M; Riera-Guardia N; Margulis AV; Varas-Lorenzo C; Calingaert B; Perez-Gutthann S
BMC Cardiovasc Disord; 2016 Jan; 16():14. PubMed ID: 26769243
[TBL] [Abstract][Full Text] [Related]
12. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
Hamid Z; Simmons DL
Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
15. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus.
Sauer WH; Cappola AR; Berlin JA; Kimmel SE
Am J Cardiol; 2006 Mar; 97(5):651-4. PubMed ID: 16490431
[TBL] [Abstract][Full Text] [Related]
16. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
17. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
[TBL] [Abstract][Full Text] [Related]
18. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
19. Cancer and bone fractures in observational follow-up of the RECORD study.
Jones NP; Curtis PS; Home PD
Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
[TBL] [Abstract][Full Text] [Related]
20. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
